Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Lessons Learned from Using Global Outcome Measures to Assess Community Pharmacy Performance.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print Cited Medium: Internet ISSN: 2376-1032 (Electronic) Linking ISSN: 23760540 NLM ISO Abbreviation: J Manag Care Spec Pharm Subsets: MEDLINE
- Publication Information:
Original Publication: Alexandria, VA : Academy of Managed Care Pharmacy, [2014]-
- Subject Terms:
- Abstract:
Introduction: As value-based and alternative payment models proliferate, there is growing interest in measuring pharmacy performance. However, little research has explored the development and implementation of systems to measure pharmacy performance. Additionally, systems that currently exist rely on process and surrogate outcome measures that are not always relevant to patients and payers.
Program Description: This article describes the process used to design and implement a performance measurement program for a group of enhanced services pharmacies in North Carolina. This program was successful in measuring quality based on medication adherence, hospitalizations, emergency department visits, and total cost of medical care for nearly all North Carolina pharmacies. Measures were scored and combined into a single 11-point composite pharmacy performance score. To demonstrate the measures, we compared performance scores for enhanced services pharmacies (n = 119) to other North Carolina pharmacies (n = 1,616) during the baseline measurement period (March 1, 2015-May 31, 2015). Adherence measure scores for enhanced services pharmacies exceeded those of other pharmacies (P values < 0.0001-0.003), but total scores were not significantly different, with enhanced services pharmacy mean total scores of 6.54 vs. 6.29 for all other pharmacies (P = 0.115).
Observations: The program described provides an example of a composite performance measurement system that can be used to support alternative pharmacy payment models and shows that case-mix adjustment is possible for broad outcomes such as those used in this program. The measures used for the program depend on timely feeds of medical claims. Payers and pharmacy networks implementing a similar program may need to explore alternative structure or process measures.
Implications: As pharmacy payment models evolve, there may be value in collaboration between academics, pharmacists, and payers to bring different areas of expertise and perspectives into the performance measurement process. This program demonstrates that global outcome measurement is possible over a broad set of pharmacies and invites additional research to explore the validity of this and other methods to measure pharmacy quality and performance.
Disclosures: The program described in this article was supported by Funding Opportunity Number 1C12013003897 from the U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services. The contents provided are solely the responsibility of the authors and do not necessarily represent the official views of HHS or any of its agencies. Community Care of North Carolina received the grant and subcontracted with the UNC Eshelman School of Pharmacy to carry out this project. Shasky, Pfeiffenberger, and Trygstad are employed by Community Care of North Carolina. Urick and Ferreri are employed by the UNC Eshelman School of Pharmacy. Farley was employed by the UNC Eshelman School of Pharmacy during data collection for this project and reports consulting fees from UCB Pharmaceutical Company unrelated to this project. Pfeiffenberger reports membership on the Pharmacy Quality Alliance (PQA) task force on pharmacy level measures; Trygstad is a PQA board member; Urick is a member of a scientific advisory committee for PQA.
- References:
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2):217-221.e1. (PMID: 28173992)
Health Aff (Millwood). 2014 Aug;33(8):1444-52. (PMID: 25092847)
Am J Med. 2013 Apr;126(4):357.e7-357.e27. (PMID: 23507208)
N Engl J Med. 2015 Mar 5;372(10):897-9. (PMID: 25622024)
Res Social Adm Pharm. 2012 Sep-Oct;8(5):360-70. (PMID: 22222347)
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2):229-235.e1. (PMID: 28173993)
N Engl J Med. 2010 Dec 23;363(26):2477-81. (PMID: 21142528)
JAMA. 1988 Sep 23-30;260(12):1743-8. (PMID: 3045356)
JAMA Intern Med. 2015 Jan;175(1):76-87. (PMID: 25401788)
Med Care. 2002 Sep;40(9):794-811. (PMID: 12218770)
Res Social Adm Pharm. 2012 May-Jun;8(3):206-16. (PMID: 21824822)
Health Aff (Millwood). 2012 Jan;31(1):120-9. (PMID: 22232102)
J Health Polit Policy Law. 2015 Aug;40(4):761-96. (PMID: 26124294)
- Publication Date:
Date Created: 20181128 Date Completed: 20190128 Latest Revision: 20230805
- Publication Date:
20230805
- Accession Number:
PMC10397585
- Accession Number:
10.18553/jmcp.2018.24.12.1278
- Accession Number:
30479196
No Comments.